View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Cerence and Vivoka Expand Collaboration to Deliver Embedded Voice AI f...

Cerence and Vivoka Expand Collaboration to Deliver Embedded Voice AI for Industrial Markets Worldwide SUMMARY AND KEY POINTS: Cerence AI and Vivoka have expanded their partner-led strategy to deliver embedded voice AI to global industrial markets, including logistics and field services.The fully embedded solution improves performance and reduces operational errors by up to 70%, supporting scalable industrial deployment.The joint solution is optimized for industrial applications with Cerence’s latest conversational AI based on neural voice technology and Vivoka’s VDK 6 Collaborative Voice A...

 PRESS RELEASE

3D Systems Reports Fourth Quarter and Full Year 2025 Financial Results

3D Systems Reports Fourth Quarter and Full Year 2025 Financial Results ROCK HILL, S.C., March 09, 2026 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2025. Fourth quarter revenue of $106.3 million grew 16% sequentially, above guidance of 8% to 10% growth, driven by a successful ramp-up of new printer system sales and higher materials consumptionFor full year 2025, the Company delivered double-digit top-line growth in personalized health services and aerospace and defense marketsCost reduc...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Tutor Perini Corp: 1 director

A director at Tutor Perini Corp bought 25,000 shares at 72.960USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

 PRESS RELEASE

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on March 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 16,500 shares o...

 PRESS RELEASE

PacBio Announces the Appointment of Chris Gibson to the Board of Direc...

PacBio Announces the Appointment of Chris Gibson to the Board of Directors Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biot...

 PRESS RELEASE

Plug Power to Ring the Nasdaq Stock Market Closing Bell on March 6, 20...

Plug Power to Ring the Nasdaq Stock Market Closing Bell on March 6, 2026 Company celebrates Plug’s strong full year 2025 results and newly appointed CEO, Jose Luis Crespo SLINGERLANDS, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, will visit the NASDAQ MarketSite in Times Square to ring the Closing Bell on Friday, March 6, 2026. The Closing Bell ceremony celebrates as well as its newly appointed CEO, Jose Luis Crespo, who officially took the helm of the company on March 2, 2026. Full-year 2025 re...

 PRESS RELEASE

Global Water Resources Reports Full Year 2025 Results

Global Water Resources Reports Full Year 2025 Results PHOENIX, March 04, 2026 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the full year ended December 31, 2025. Unless otherwise noted, all comparisons are to the corresponding period in the prior year. The company will hold a conference call at 1:00 p.m. Eastern time tomorrow to discuss the results (see dial-in information below). Financial Highlights Total revenue increased 5.8% year-over-year (“YoY”) to $55.8 million. The increase was primarily due...

 PRESS RELEASE

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303...

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08 NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee. Effective March 1, 2026, in connection with commencing employment as Chief Growth Officer, U.S. Group Health, Daniel Conroy was granted an award of restricted stock units covering 57,034 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and an award of performance stock units covering a target of 5...

 PRESS RELEASE

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq ...

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 2, 2026, the Company granted restricted stock units (RSUs) representing 50,700 shares of its common stock to three newly-hired non-executive employees. The grants were appr...

 PRESS RELEASE

Vericel Announces FDA Approval of New State-of-the-Art Advanced Therap...

Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for MACI® (autologous cultured chond...

Camtek: 1 director

A director at Camtek sold 677 shares at 167.390USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Cl...

Tutor Perini Corporation: Update following upgrade

Our credit view of this issuer reflects its improved credit metrics.

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

4Q25 Postmortem: Evaluating AI Risk in the Current Landscape

In this report, we establish an initial framework to assess exposure to AI-enabled risk across our coverage group. Specifically, we evaluate the risk of replacement, disintermediation, or both. Our framework measures structural defensibility and business model differentiation against the difficulty

 PRESS RELEASE

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healt...

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida. Management ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch